F2 Ventures
VC Fund
London, United Kingdom
F2 Ventures is a healthcare investment platform focused on arbitrage opportunities across the biotech sector, targeting innovation at the right stage for maximum impact.
- Total investments:
- 28
- Last investment:
- Lead investor:
- 21%
Last updated:
For AI agents: llms.txt
Industries F2 Ventures invests in
Stages F2 Ventures invests in
Countries F2 Ventures invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
4 more contacts available
Round size
- Series A
- $11M–$300M
- Series B
- $3M–$170M
- Series C
- $21M–$525M
Investment Focus
Industry
- Biotechnology 9 (32%)
- Pharmaceutical 6 (21%)
- Therapeutics 4 (14%)
- Clinical Trials 4 (14%)
- Medical 3 (11%)
Stage
- Series B 8 (29%)
- Series A 7 (25%)
- Series C 4 (14%)
- Series D 3 (11%)
- Post-IPO Equity 2 (7%)
Country
- United States 11 (39%)
- Israel 4 (14%)
- Malaysia 1 (4%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Morana Jovan-Embiricos
Managing Partner & Founder
|
Managing Partner & Founder | Total investments: 3 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
ElevateBio
|
ElevateBio is an operator of a portfolio of cell and gene therapy companies intended to develop, manufacture, and commercialize life-transforming medicines.The company creates a portfolio through partnerships with the world's innovative scientists and inventors as well as it created a centralized facility that integrates all the elementsthat translate cell and gene therapy R&D into commercially viable therapies quickly and efficiently, enabling patients to get medical products to treat severe diseases.Vikas Sinha, Mitchell Finer, and David Hallal co-founded ElevateBio in Cambridge, Massachusetts in 2017. | $401M / Series D / May 24, 2023 | |
ReNAgade Therapeutics
|
ReNAgade Therapeutics focuses on the boundless potential of RNA therapeutics to treat disease. RNA delivery systems with a comprehensive RNA platform that allows for an all-RNA system for coding, editing, and gene insertion to produce new medications. | $300M / Series A / May 23, 2023 | |
4M Analytics
|
4M ANALYTICS is a subsurface-infrastructure geo-data company.We developed a mapping engine for utility and infrastructure construction project life cycle, for the pre planning and planning phase,an early comprehensive, mapping simulation tool before the project handed off to the design builder and constructor.Our technology is powered bydeep expertise in applying AI and analytics to satellite and aerial imagery analysis for the civil engineering domain. We provide complete, accurate and up to date subsurface infrastructure maps.Our maps are created remotely using AI, without the need for prior as-built data, anywhere in the world and at unprecedented scale and super low cost. | $30M / Series A / Sep 19, 2022 | |
Kalaris Therapeutics
|
AlloVir focuses on the development of cell therapies and focuses on restoring natural immunity against the virus-associated diseases. It provides an ideal environment for ViraCyte to develop and advance its product pipeline from discovery through late-stage clinical trials. The company was founded in 2013 and headquartered in Houston, Texas. | $126.6M / Post-IPO Equity / Jul 27, 2022 | |
Kalaris Therapeutics (formerly AlloVir)
|
AlloVir focuses on the development of cell therapies and focuses on restoring natural immunity against the virus-associated diseases. It provides an ideal environment for ViraCyte to develop and advance its product pipeline from discovery through late-stage clinical trials. | $126.6M / Post-IPO Equity / Jul 27, 2022 | |
Justt
|
Justt turns a clunky and cumbersome credit card dispute process into one that’s fair, simple and hands-free for merchants. Using machine learning and deep domain knowledge, Justt effortlessly flags incorrect chargebacks, and builds tailored solutions to gather and submit evidence on merchants’ behalf. | $70M / Series B / Nov 16, 2021 | |
Justt
|
Justt turns a clunky and cumbersome credit card dispute process into one that’s fair, simple and hands-free for merchants. Using machine learning and deep domain knowledge, Justt effortlessly flags incorrect chargebacks, and builds tailored solutions to gather and submit evidence on merchants’ behalf. | $50M / Series B / Nov 16, 2021 | |
Five Sigma
|
Five Sigma is a cloud-native, data-driven Claims Management Solution (CMS) with embedded AI/ML capabilities to allow simple and smart claims processing for the insurance industry. Five Sigma simplifies claims management by adding automated claims processing workflows and using data modeling and AI to provide smart recommendations – improvingadjusters’ decision-making and reducing errors. Leading insurance carriers, Insurtech, TPAs and Self-Insured companies use Five Sigma's CMS to modernize their claims operations, reduce claims leakage, enhance compliance, and improve their customer experience. | $12M / Series A / Sep 13, 2021 | |
|
4M Analytics
|
4M ANALYTICS is a subsurface-infrastructure geo-data company.We developed a mapping engine for utility and infrastructure construction project life cycle, for the pre planning and planning phase,an early comprehensive, mapping simulation tool before the project handed off to the design builder and constructor.Our technology is powered bydeep expertise in applying AI and analytics to satellite and aerial imagery analysis for the civil engineering domain. We provide complete, accurate and up to date subsurface infrastructure maps.Our maps are created remotely using AI, without the need for prior as-built data, anywhere in the world and at unprecedented scale and super low cost. | $11M / Series A / Aug 09, 2021 | |
|
ElevateBio
|
ElevateBio is an operator of a portfolio of cell and gene therapy companies intended to develop, manufacture, and commercialize life-transforming medicines.The company creates a portfolio through partnerships with the world's innovative scientists and inventors as well as it created a centralized facility that integrates all the elementsthat translate cell and gene therapy R&D into commercially viable therapies quickly and efficiently, enabling patients to get medical products to treat severe diseases.Vikas Sinha, Mitchell Finer, and David Hallal co-founded ElevateBio in Cambridge, Massachusetts in 2017. | $525M / Series C / Mar 15, 2021 | |
| See all 28 investments → | |||
Co-Investors
MPM Capital
16 deals together
Redmile Group
8 deals together
EcoR1 Capital
6 deals together
Invus
6 deals together
Samsara BioCapital
5 deals together
EDBI
3 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does F2 Ventures invest in?
F2 Ventures invests primarily in Biotechnology, Pharmaceutical and Therapeutics startups, most often at Series B and Series A stage. Most of the 28 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is F2 Ventures's check size?
F2 Ventures typically joins rounds of $11M–$300M at Series A, $3M–$170M at Series B and $21M–$525M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds F2 Ventures participates in.
How do I contact F2 Ventures?
Public channels for F2 Ventures include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at F2 Ventures?
The team at F2 Ventures includes Morana Jovan-Embiricos (Managing Partner & Founder). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
